anonymous
Guest
anonymous
Guest
Not worth your time. They sell nine months of a generic steroid from the 1990s with marginal benefits for $150,000.
They have cash flow issues, the pay is low and culture is trash. Unlikely they will last long.
I moved on to another company with an innovative renal product.
Don’t disagree with info about the company, but the drug serves a purpose and has more benefit than anything else for the right patient.
If your move was to Novartis, good luck with that one. Complement inhibitors are already being designated as a last resort after Tarpeyo. Then you’ve got Dez who will metric & big pharma the hell out of everyone. Not that I wouldn’t have taken the job. Still well worth the extra pay and benes that Novartis offers!